Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/6/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
(NASDAQ: NVCT) Delayed: 24.49 +0.12 (0.49%)
Previous Close $24.37    52 Week High $ 
Open $24.00    52 Week Low $ 
Day High $25.19    P/E N/A 
Day Low $23.96    EPS $ 
Volume 117,166